Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
Mirum Pharmaceuticals MIRM announced that it has completed enrollment in the phase III EXPAND study, which evaluated Livmarli (maralixibat) for treating cholestatic pruritus in patients aged six months and above with rare cholestatic liver diseases, including biliary atresia. The primary endpoint of the EXPAND study is to see the change in pruritus severity from baseline to week 20, while secondary endpoints include changes in serum bile acids and other markers of cholestatic liver disease. The double-blind, placebo-controlled phase III study is designed to support a potential label expansion of Livmarli into additional settings of cholestatic pruritus. Top-line data from the same is expected in the fourth quarter of 2026. Livmarli, is an orally administered ileal bile acid transporter (“IBAT”) inhibitor currently approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive fami
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (TVTX) had its price target lowered by JPMorgan Chase & Co. from $44.00 to $41.00. They now have an "overweight" rating on the stock.MarketBeat
- Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics, Inc. (TVTX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms [Seeking Alpha]Seeking Alpha
- Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 3/18/26 - Form 4
- 3/16/26 - Form 144
- 2/24/26 - Form 4
- TVTX's page on the SEC website